Longitude Capital Partners III, LLC - Jan 25, 2022 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
10%+ Owner
Signature
Longitude Venture Partners III, L.P.; By /s/ Patrick G. Enright, Managing Member
Stock symbol
SRRA
Transactions as of
Jan 25, 2022
Transactions value $
-$13,063,697
Form type
4
Date filed
1/27/2022, 08:23 PM
Previous filing
May 11, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Exercise of in-the-money or at-the-money derivative security $6.43M +487K +33% $13.20 1.96M Jan 25, 2022 See footnote F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Series B Warrants Exercise of in-the-money or at-the-money derivative security -$19.5M -1.48M -100% $13.20 0 Jan 25, 2022 Common Stock 487K $13.20 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held directly by Longitude Venture Partners III, L.P. ("LVP III"). Longitude Capital Partners III, LLC ("LCP III") is the general partner of LVP III and may be deemed to have voting, investment and dispositive power with respect to such securities. Patrick G. Enright, Juliet Tammenoms Bakker and Joshua Richardson, a member of the Issuer's board of directors, are each members of LCP III and may be deemed to share voting, investment and dispositive power over such securities. Mr. Enright and Ms. Tammenoms Bakker are the managing members of LCP III. Each of LCP III, Mr. Enright, Ms. Tammenoms Bakker and Joshua Richardson disclaim beneficial ownership over such securities except to the extent of their respective pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
F2 Consists of 1,477,125 Series B Warrants held by LVP III which are exercisable for an aggregate of 487,451 shares of Common Stock.